Core Insights - The World Internet Conference in Wuzhen focuses on "Artificial Intelligence," showcasing innovations in the medical field, including the AnDun Life Warning Watch, which addresses healthcare challenges [1][7] - AnDun's Life Warning Watch utilizes the proprietary "Tianhui AI Pulse Diagnosis Algorithm" to provide risk warnings for major diseases and monitor multiple organ functions, creating a personalized health assessment system [2][5] - The fifth generation of AnDun's product line, the X5, is set to launch in Q1 of next year, featuring significant upgrades in core algorithms and user experience to enhance proactive health management [5] - AnDun's founder emphasizes the transformative impact of AI across industries and the company's commitment to integrating AI with traditional Chinese medicine to standardize and visualize health management [5][7] - AnDun's participation in the conference highlights China's advancements in AI healthcare and supports the "Healthy China" initiative, indicating a growing trend of AI in health management [7]

Group 1 - The event "Scientists Meet Investors" showcased innovative technologies from three technology companies in materials science, plasma medicine, and AI healthcare, demonstrating the integration of academic research and market needs [1][2][3] - Xi'an Qinguang Zhichai Technology Co., Ltd. presented a "long-life heavy anti-corrosion technology integrated solution," which enhances metal protection in extreme environments and has a lifespan increase of 5-10 times, with applications in marine engineering and chemical facilities [1][2] - West Xi'an Cold Plasma Technology Co., Ltd. focuses on low-temperature plasma technology for medical applications, achieving rapid sterilization and targeting difficult skin conditions, with plans to expand into human health products and AI diagnostic systems [2][3] Group 2 - Shandong Shuying Intelligent Medical Technology Co., Ltd. introduced an "AI-enabled minimally invasive imaging solution," which improves surgical precision and efficiency through real-time analysis of surgical images, with ongoing clinical trials in multiple hospitals [2][3] - The event highlighted the potential for collaboration between scientists and investors to drive innovation in the "hard technology" industry, emphasizing the importance of transforming academic achievements into practical applications [3]

Core Viewpoint - The National Health Commission has released implementation opinions to promote and standardize the application of "Artificial Intelligence + Healthcare," aiming for high-quality development in the health sector by 2027 and 2030 [1][2]. Group 1: Implementation Goals - By 2027, a series of high-quality data sets and trusted data spaces will be established in the health sector, along with the formation of clinical specialty vertical large models and intelligent applications [1][2]. - By 2030, intelligent auxiliary applications for grassroots diagnosis and treatment will achieve full coverage, with secondary hospitals widely adopting AI technologies for medical imaging and clinical decision-making [1][2]. Group 2: Key Applications - Strengthening intelligent applications in grassroots healthcare, focusing on resource-sharing centers for medical imaging, ECG diagnosis, and chronic disease management [3]. - Establishing intelligent auxiliary diagnosis applications for common diseases at the grassroots level, enhancing the diagnostic capabilities of primary care physicians [3]. - Promoting intelligent medical imaging diagnostic services, encouraging hospitals to develop multi-disease applications from single disease models [4][5]. Group 3: Patient Services - Optimizing patient service processes with intelligent appointment scheduling, pre-consultation, and follow-up services to improve patient experience [6]. - Supporting the establishment of intelligent referral information systems to allocate resources effectively based on patient needs and hospital capacities [6]. Group 4: Traditional Chinese Medicine (TCM) - Enhancing intelligent TCM diagnostic applications by building knowledge bases and supporting the development of AI models for TCM [7]. - Promoting intelligent management of traditional Chinese medicine throughout its lifecycle, including cultivation, production, and usage [7]. Group 5: Public Health - Strengthening infectious disease monitoring and early warning systems through AI, providing real-time support for public health decision-making [8]. - Enhancing emergency management and response capabilities in public health through AI applications [8]. Group 6: Research and Education - Promoting intelligent applications in medical research to improve efficiency and quality in various research processes [9]. - Expanding health education services through personalized health knowledge dissemination and innovative knowledge provision for healthcare professionals [9]. Group 7: Industry Governance - Promoting intelligent management in healthcare institutions, focusing on quality, cost management, and resource allocation [11]. - Strengthening regulatory frameworks for AI applications in healthcare, ensuring safety and compliance [15]. Group 8: Health Industry Development - Encouraging the development of new intelligent service models in health consumption, including health management and consultation services [12]. - Supporting innovation in intelligent medical equipment and information technology within the healthcare sector [12]. Group 9: Infrastructure and Data - Building a comprehensive health information platform to connect various healthcare institutions and improve data sharing [13]. - Enhancing the supply of medical data and optimizing data collection processes for better AI application [13]. Group 10: Talent and Standards - Strengthening the training of AI professionals in the health sector and establishing a robust policy framework for AI applications [14]. - Promoting pilot projects to facilitate the practical application of AI in healthcare [16].

Core Insights - The company has not developed brain-computer interface technology and equipment but is utilizing it as an auxiliary tool for its smart medical business [1] - The company aims to develop a closed-loop brain-machine interface (BMI) system based on optogenetic control to meet the needs of smart anesthesia and smart rehabilitation applications [1] Business Development - In 2022, the company established the "Brain Cognition and Smart Medical Innovation Application Laboratory" approved by Chengdu, focusing on key technologies in artificial intelligence and medical engineering [1] - The laboratory is building platforms for technology research and development, business development, and mobile application development, with plans to upgrade products in smart anesthesia assistance, IoT medical devices, integrated regional smart medical and health platforms, and rehabilitation products [1] Strategic Partnerships - The company is collaborating with the Suzhou Institute of Nano-Tech and Nano-Bionics of the Chinese Academy of Sciences to establish a brain-like intelligence and smart medical industry-university-research center [1] - This partnership aims to conduct research on key technologies and innovative applications, targeting clinical auxiliary diagnosis and treatment, clinical scientific research, and regional health and wellness applications [1] Financial Performance - In the first half of 2025, the company achieved revenue of 142 million yuan, a year-on-year decrease of 6.61% [1] - The net profit attributable to the parent company was 4 million yuan, down 24.48% year-on-year [1]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並表明概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致的任 何損失承擔任何責任。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件所載資料作出投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不會引致本公司、其聯席 保薦人、整體協調人、顧問或包銷團成員須於香港或任何其他司法管轄區進行發售活動 的責任。本公司最終會否進行任何發售仍屬未知之數； (c) 本文件或其補充、修訂或更換附頁的內容未必會全部或部分轉載於最終正式上市文件； (d) 本申請版本並非最終上市文件，本公司可能會不時根據《香港聯合交易所有限公司證券上 市規則》作出更新或修訂； (e) 本文件並非向任何司法管轄區的公眾人士提呈出售任何證券的招股章程、發售通函、通 告、通函、小冊子或廣告，亦非邀請公眾人士提出認購或購買任何證券的要約，且並非 旨在邀請公眾人士提出認購或購買任何證券的要約； (f) 本文件不應被視為勸誘認購或購買任何證券，亦不擬構成該等勸誘； ...

Core Insights - The Fourth Global Digital Trade Expo's Digital Healthcare Industry Matching Conference was held on September 25 in Hangzhou, highlighting advancements in medical AI [1] - The establishment of a joint laboratory for medical AI evaluation and verification aims to create a "gold standard" for the compliant, safe, and efficient application of AI in healthcare [1] - A global recruitment plan for innovative entrepreneurial teams in the medical AI sector has been launched, providing R&D space, funding, and policy support to attract high-quality AI medical projects [1] Group 1 - The joint laboratory is a collaboration between the Zhejiang Provincial National AI Application Pilot Base, the Chinese Academy of Medical Sciences, and the China Academy of Information and Communications Technology [1] - The initiative aims to facilitate the entire development chain of medical AI from concept validation to industrial implementation [1] - The recruitment plan is designed to attract global talent and projects to enhance the medical AI landscape in Zhejiang [1]

Core Insights - The integration of VR and AI in healthcare is leading to a quiet revolution, redefining the boundaries of health and wellness, with applications ranging from pain relief to treating Alzheimer's disease [1][12] - Walter Greenleaf, a leading expert in VR and digital health, emphasizes the importance of translating laboratory results into market applications to aid startups in scaling their innovations [2] - Immersive therapies are emerging as a new class of treatment, utilizing VR and AR to help patients overcome psychological barriers in a safe environment [4] Group 1: Immersive Therapy Applications - Immersive therapies are being used for PTSD treatment, addiction recovery, and social training for children with autism, showcasing the potential of VR and AR as "second-generation drugs" [4] - The concept of "on-demand experiences" allows patients to enter virtual worlds that facilitate gradual exposure to their fears and anxieties [4] Group 2: Aging Population and Investment Opportunities - By 2050, one in six people will be over 65, highlighting the need for solutions that maintain brain vitality as longevity increases [6] - The focus on brain health is becoming a more critical investment topic than wealth accumulation, with sleep being identified as a key factor [6] Group 3: China's Opportunities in AI and Healthcare - China possesses significant advantages in AI and healthcare technology, particularly in precision medicine and data application, positioning it for rapid advancements in these fields [8] Group 4: Digital Therapeutics and Regulatory Changes - The FDA has established a new category for "software as a medical device," allowing for the prescription of software, indicating a shift towards mainstream acceptance of digital therapies [10] - The next 5-10 years are expected to see the scaling of immersive medical applications within healthcare systems [10]

Core Insights - The integration of AI in healthcare is progressing, with large pre-trained language models being implemented in hospitals across China, indicating a shift from theoretical applications to practical use in clinical settings [1][2][3] - The market for medical large models is expected to grow significantly, with projections estimating a market size of nearly 2 billion yuan by 2025 and an annual growth rate of 140% [3] - Despite advancements, the transition from medical large models to fully autonomous AI doctors faces challenges, including technical limitations, data availability, and societal acceptance [4][8][10] Group 1: Medical Model Implementation - Major hospitals in China have begun using AI models for diagnostics, with examples of successful applications in pediatric care demonstrating improved diagnostic accuracy [2][3] - Policies supporting AI in healthcare have been introduced, including guidelines for AI-assisted diagnosis and integration into medical service pricing [2][3] - The AI system "智医助理" has been deployed in over 75,000 grassroots medical institutions, providing over 1 billion diagnostic suggestions, thereby alleviating the burden on healthcare professionals [3] Group 2: Challenges and Limitations - The definition of AI doctors remains ambiguous, with a distinction made between medical large models and AI doctors, the latter requiring practical clinical experience [6][7] - Technical challenges persist, such as the "black box" nature of models and the risk of incorrect diagnoses, which can lead to serious consequences for patients [8][9] - Data scarcity and fragmentation hinder the development of effective medical large models, particularly in rare disease diagnostics where accuracy is often below 60% [9] Group 3: Societal Acceptance and Future Directions - Public skepticism towards AI in healthcare remains, with patients often preferring human doctors despite the capabilities of AI models [10] - Experts suggest that enhancing the credibility of AI through clinical outcomes, research publications, and transparent methodologies is essential for gaining acceptance [14] - Recommendations for policy adjustments include simplifying AI product registration processes and integrating AI services into health insurance systems to foster collaboration between medical institutions and technology companies [15]

Core Viewpoint - Yidu Technology (02158) has recently won a bid for a Phase III clinical research project for the human nerve growth factor (SMR001) eye drops, with a total project amount of approximately RMB 55.82 million [1] Group 1: Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] Group 2: AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, providing doctors with precise decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and offering affordable precision diagnosis and treatment for patients [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

Core Viewpoint - The interview highlights the transformative impact of AI technology on the medical imaging market, emphasizing its current role in clinical decision support and the regulatory challenges faced in the industry [2] Industry Overview - AI in healthcare is primarily applied in decision support scenarios, with most products classified as high-risk and managed under Class III medical devices, which have distinct approval and clinical evaluation requirements compared to traditional medical products [2] - Over 100 AI Class III products have been approved by the National Medical Products Administration, predominantly featuring single-model and single-scenario applications [2] Regulatory Environment - The medical field's seriousness, complexity, and low tolerance for error necessitate caution in defining the intended use of medical AI products, with applications limited to specific disease areas such as lung cancer or prostate cancer for auxiliary detection and diagnosis [2] - The company is actively involved in shaping regulatory guidelines and industry standards alongside the National Medical Products Administration, aiming to contribute practical experience to support the industry's normative development [2] Technological Development - The rapid advancement of AI technology, particularly large models, presents new challenges and transformations for the industry [2] - Currently, AI products based on large models have not yet been implemented in complex clinical scenarios, both domestically and internationally [2]